{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-027706","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.591910+00:00","generated_at":"2026-05-26T03:28:14.911830+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kura Oncology reports Q4 net loss $19.2M; KOMET-001 trial hits primary endpoint; NDA plan Q2 2025","bullets":["Q4 collaboration revenue $53.9M (from Kyowa Kirin), R&D $52.3M, net loss $19.2M vs $42.8M YoY.","KOMET-001 achieved primary endpoint with 20-30% CR/CRh rate in R/R NPM1-mutant AML; NDA submission expected Q2 2025.","FDA and EMA aligned on KOMET-017 Phase 3 protocol using MRD-negative CR for potential accelerated U.S. approval; topline 2028.","Cash, equivalents and short-term investments $727.4M as of Dec 31, 2024; sufficient into 2027 with Kyowa funding.","KOMET-007 Phase 1: 91% CR in 1L adverse-risk AML cohort with intensive chemo (7+3) combination."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-027706","json":"https://secwatch.observer/filing/0000950170-25-027706.json","markdown":"https://secwatch.observer/filing/0000950170-25-027706.md","text":"https://secwatch.observer/filing/0000950170-25-027706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/0000950170-25-027706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025027706/kura-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:28:14.911830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}